Immutep
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immutep and other ETFs, options, and stocks.About IMMP
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731).
CEOMarc Voigt
CEOMarc Voigt
Employees—
Employees—
HeadquartersSydney, New South Wales (NSW)
HeadquartersSydney, New South Wales (NSW)
Founded1987
Founded1987
Employees—
Employees—
IMMP Key Statistics
Market cap295.00M
Market cap295.00M
Price-Earnings ratio-9.31
Price-Earnings ratio-9.31
Dividend yield—
Dividend yield—
Average volume1.35M
Average volume1.35M
High today$2.10
High today$2.10
Low today$1.95
Low today$1.95
Open price$2.01
Open price$2.01
Volume107.54K
Volume107.54K
52 Week high$3.34
52 Week high$3.34
52 Week low$1.32
52 Week low$1.32
IMMP News
TipRanks 2d
Immutep’s Efti Combination Shows Promising Results in Lung Cancer TrialConfident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive underval...
Benzinga 2d
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple ComboImmutep Limited IMMP on Thursday announced additional data from the investigator-initiated INSIGHT-003 trial evaluating a triple combination therapy in front-li...
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%